JPWO2023210741A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023210741A5
JPWO2023210741A5 JP2024518025A JP2024518025A JPWO2023210741A5 JP WO2023210741 A5 JPWO2023210741 A5 JP WO2023210741A5 JP 2024518025 A JP2024518025 A JP 2024518025A JP 2024518025 A JP2024518025 A JP 2024518025A JP WO2023210741 A5 JPWO2023210741 A5 JP WO2023210741A5
Authority
JP
Japan
Prior art keywords
group
methyl
dihydro
ethyl
benzotriazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024518025A
Other languages
English (en)
Japanese (ja)
Other versions
JP7605446B2 (ja
JPWO2023210741A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/016629 external-priority patent/WO2023210741A1/ja
Publication of JPWO2023210741A1 publication Critical patent/JPWO2023210741A1/ja
Publication of JPWO2023210741A5 publication Critical patent/JPWO2023210741A5/ja
Application granted granted Critical
Publication of JP7605446B2 publication Critical patent/JP7605446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024518025A 2022-04-28 2023-04-27 ベンゾトリアゾール化合物 Active JP7605446B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022075223 2022-04-28
JP2022075223 2022-04-28
PCT/JP2023/016629 WO2023210741A1 (ja) 2022-04-28 2023-04-27 ベンゾトリアゾール化合物

Publications (3)

Publication Number Publication Date
JPWO2023210741A1 JPWO2023210741A1 (cg-RX-API-DMAC7.html) 2023-11-02
JPWO2023210741A5 true JPWO2023210741A5 (cg-RX-API-DMAC7.html) 2024-11-26
JP7605446B2 JP7605446B2 (ja) 2024-12-24

Family

ID=88518776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518025A Active JP7605446B2 (ja) 2022-04-28 2023-04-27 ベンゾトリアゾール化合物

Country Status (12)

Country Link
US (3) US20250282724A1 (cg-RX-API-DMAC7.html)
EP (1) EP4509504A4 (cg-RX-API-DMAC7.html)
JP (1) JP7605446B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250004844A (cg-RX-API-DMAC7.html)
CN (1) CN119173511A (cg-RX-API-DMAC7.html)
AU (1) AU2023259936A1 (cg-RX-API-DMAC7.html)
CA (1) CA3256688A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014914A2 (cg-RX-API-DMAC7.html)
IL (1) IL316449A (cg-RX-API-DMAC7.html)
MX (1) MX2024013242A (cg-RX-API-DMAC7.html)
WO (1) WO2023210741A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408061B (cg-RX-API-DMAC7.html)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021676A1 (ja) 2009-08-21 2011-02-24 大塚製薬株式会社 ベンゾ[b][1,4]ジアゼピン-2,4-ジオン化合物の製造方法
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
MY174747A (en) 2013-04-11 2020-05-13 Hoffmann La Roche Bace1 inhibitors
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
CN105294654B (zh) 2014-05-30 2018-01-09 北京浦润奥生物科技有限责任公司 Alk激酶抑制剂及其制备方法和应用
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) * 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
US11643407B2 (en) 2018-05-23 2023-05-09 Glaxosmithkline Intellectual Property Development Limited Indanes as NRF2 activators
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
EP3953337A4 (en) * 2019-04-08 2023-08-09 Dana-Farber Cancer Institute, Inc. Degraders of kelch-like ech-associated protein 1 (keap1)
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
WO2021002473A1 (ja) * 2019-07-03 2021-01-07 千寿製薬株式会社 Nrf2活性化化合物

Similar Documents

Publication Publication Date Title
US11912686B2 (en) LPA receptor antagonists and uses thereof
JP7591066B2 (ja) Lpa受容体アンタゴニスト及びそれらの使用
CN106061978B (zh) 用于治疗和预防乙型肝炎病毒感染的新的6-稠合的杂芳基二氢嘧啶
RU2655914C9 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP5820056B2 (ja) Cetp阻害剤としてのシクロアルケニルアリール誘導体
AU2008314963A1 (en) Oxadiazolidinedione compound
JP7476216B2 (ja) ファルネソイドx受容体モジュレータとしての置換二環式化合物
CN106795147B (zh) 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
RU2005125209A (ru) Производные пирролопиридазина
JP2013542937A5 (cg-RX-API-DMAC7.html)
CN102112453A (zh) 新的钾通道阻断剂及其用途
JPWO2010001946A1 (ja) トリアゾール誘導体またはその塩
KR20190129034A (ko) 금속효소 억제제 화합물
JP2020503332A5 (cg-RX-API-DMAC7.html)
RU2746001C2 (ru) Производные 3-(6-хлор-3-оксо-3,4-дигидро-(2h)-1,4-бензоксазин-4-ил)пропионовой кислоты и их применение в качестве ингибиторов kmo
JP7494222B2 (ja) ピリジン-3-イル誘導体
JP7048601B2 (ja) mGluR7調節疾患、障害、または病状を処置するためのmGluR7アゴニスト化合物
JPWO2023210740A5 (cg-RX-API-DMAC7.html)
AU2015367396B2 (en) 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors
RU2024129723A (ru) Соединение бензотриазола
CN111936488A (zh) 用于治疗寄生虫感染的新颖化合物
JP7697966B2 (ja) 抗ウイルス1,3-ジ-オキソ-インデン化合物
CA3185689C (en) Lpa receptor antagonists and uses thereof
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
JP2018515571A (ja) 3−(5−クロロ−2−オキソ−2,3−ジヒドロ−1,3−ベンゾチアゾール−3−イル)プロパン酸誘導体およびそれらのkmo阻害剤としての使用